IP Library Granted Patent US 10,124,019
Granted Patent B2
US 10,124,019 · App. 14/865,712 · Granted Nov 13, 2018

Compositions and their use for removing cholesterol

Inventors: Frederick Maxfield (Chappaqua, NY); J. David Warren (New York, NY)
Assignee: Cornell University
A61K31/724A61K31/165A61K31/4045A61K31/715A61K31/721A61K47/549A61K47/61
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,124,019
App. No.
14/865,712
Granted
Nov 13, 2018
Kind
B2
Abstract

The invention is directed to compositions that function to remove cholesterol from a mammal suffering from an elevated cholesterol level. The composition includes a polysaccharide having attached thereto at least one cyclic oligosaccharide. In a particular embodiment, the foregoing composition further includes at least one cell-targeting agent. The invention is also directed to methods that utilize these compositions for removing or reducing cholesterol and other lipids in a mammal suffering from an elevated level of cholesterol and/or other lipid.

Claims (22)

1. A method for lowering a cholesterol level in a patient, the method comprising administering to said patient a composition consisting essentially of a therapeutically effective amount of a polysaccharide having attached thereto at least one cyclodextrin and a cell-targeting agent, wherein said cyclodextrin is an alkylated cyclodextrin having at least one hydroxyl group of the cyclodextrin modified by substitution of a hydrogen atom of the hydroxyl group with a hydrocarbon group.

2. A method for treating a mammal suffering from a lysosomal storage disorder resulting in an accumulation of lipids, the method comprising administering to said mammal a polymer composition comprising an active portion comprising a polysaccharide having attached thereto at least one cyclodextrin.

3. The method of claim 2 , wherein said polymer composition further comprises a cell-targeting agent attached to said active portion.

4. The method of claim 2 , wherein said lysosomal storage disorder is a Niemann-Pick disease.

5. The method of claim 1 , wherein said at least one cyclodextrin is attached as a pendant group from the polysaccharide.

6. The method of claim 1 , wherein said alkylated cyclodextrin is a permethylated cyclodextrin.

7. The method of claim 1 , wherein said alkylated cyclodextrin is a hydroxypropyl cyclodextrin.

8. The method of claim 1 , wherein said cell-targeting agent targets an entity residing on a surface of a cell.

9. The method of claim 1 , wherein said cell-targeting agent targets a lysosome.

10. The method of claim 9 , wherein said cell-targeting agent is mannose-6-phosphate.

11. The method of claim 1 , wherein said polysaccharide is a dextran.

12. The method of claim 1 , wherein said polysaccharide has a molecular weight of at least 40,000 Da.

13. The method of claim 2 , wherein said at least one cyclodextrin is attached as a pendant group from the polysaccharide.

14. The method of claim 2 , wherein said cyclodextrin is an alkylated cyclodextrin by having at least one hydroxyl group of the cyclodextrin modified by substitution of a hydrogen atom of the hydroxyl group with a hydrocarbon group.

15. The method of claim 14 , wherein said alkylated cyclodextrin is a permethylated cyclodextrin.

16. The method of claim 14 , wherein said alkylated cyclodextrin is a hydroxypropyl cyclodextrin.

17. The method of claim 3 , wherein said cell-targeting agent targets an entity residing on a surface of a cell.

18. The method of claim 3 , wherein said cell-targeting agent targets a lysosome.

19. The method of claim 18 , wherein said cell-targeting agent is mannose-6-phosphate.

20. The method of claim 2 , wherein said polysaccharide is a dextran.

21. The method of claim 2 , wherein said polysaccharide has a molecular weight of at least 40,000 Da.

22. The method of claim 1 , wherein said cyclodextrin is unloaded when administered to the patient.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jul 25, 2016
From: CORNELL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039452/0094 →
Continuity (3)
Division 13322793
Provisional Application 61181996 · May 28, 2009
Related Publication 20160143942A1 · May 26, 2016